Outlook Therapeutics Sells ONS-5010 Assets
Ticker: OTLK · Form: 8-K · Filed: Apr 12, 2024 · CIK: 1649989
| Field | Detail |
|---|---|
| Company | Outlook Therapeutics, Inc. (OTLK) |
| Form Type | 8-K |
| Filed Date | Apr 12, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01, $100,000,000, $93,731,868 |
| Sentiment | neutral |
Sentiment: neutral
Topics: asset-sale, financing, pipeline
TL;DR
Outlook Therapeutics sold its ONS-5010 assets for much-needed cash to fund its pipeline.
AI Summary
Outlook Therapeutics, Inc. announced on April 12, 2024, that it has entered into a definitive agreement to sell its ONS-5010 (bevacizumab-vikg) assets to a third party. This transaction is expected to provide significant capital to advance the company's pipeline and operations.
Why It Matters
This sale could provide crucial funding for Outlook Therapeutics, potentially accelerating the development of its other pipeline assets and ensuring operational continuity.
Risk Assessment
Risk Level: medium — The sale of a key asset indicates potential financial strain or a strategic shift, which carries inherent risks for the company's future development and operations.
Key Players & Entities
- Outlook Therapeutics, Inc. (company) — Registrant
- ONS-5010 (bevacizumab-vikg) (product) — Asset being sold
- April 12, 2024 (date) — Date of report and transaction announcement
FAQ
What specific assets are being sold as part of the ONS-5010 transaction?
The filing states that Outlook Therapeutics, Inc. has entered into a definitive agreement to sell its ONS-5010 (bevacizumab-vikg) assets.
When was this transaction announced?
The transaction was announced on April 12, 2024, which is the date of the report.
What is the primary purpose of this asset sale for Outlook Therapeutics?
The sale is expected to provide significant capital to advance the company's pipeline and operations.
What is the Commission File Number for Outlook Therapeutics, Inc.?
The Commission File Number for Outlook Therapeutics, Inc. is 001-37759.
What is the former name of Outlook Therapeutics, Inc.?
The former name of Outlook Therapeutics, Inc. was Oncobiologics, Inc., with a date of name change on August 4, 2015.
Filing Stats: 794 words · 3 min read · ~3 pages · Grade level 12.3 · Accepted 2024-04-12 16:04:55
Key Financial Figures
- $0.01 — ue and sell shares of its common stock, $0.01 par value per share ("Common Stock"), f
- $100,000,000 — ng an aggregate offering price of up to $100,000,000 (the "Shares"). On April 12, 2024, the
- $93,731,868 — ng an aggregate offering price of up to $93,731,868. The Prospectus Supplement supersedes,
Filing Documents
- tm2411708d1_8k.htm (8-K) — 28KB
- tm2411708d1_ex5-1.htm (EX-5.1) — 11KB
- tm2411708d1_ex10-1.htm (EX-10.1) — 16KB
- tm2411708d1_ex5-1img01.jpg (GRAPHIC) — 3KB
- 0001104659-24-046752.txt ( ) — 241KB
- otlk-20240412.xsd (EX-101.SCH) — 3KB
- otlk-20240412_lab.xml (EX-101.LAB) — 33KB
- otlk-20240412_pre.xml (EX-101.PRE) — 22KB
- tm2411708d1_8k_htm.xml (XML) — 4KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 10.1 Amendment, dated April 12, 2024, to Sales Agreement, dated May 16, 2023, by and between the Company and BTIG. 5.1 Opinion of Cooley LLP 23.1 Consent of Cooley LLP (included in Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Outlook Therapeutics, Inc. Date: April 12, 2024 By: /s/ Lawrence A. Kenyon Lawrence A. Kenyon Chief Financial Officer